Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
Sign Up to like & getrecommendations! Published in 2022 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12159
Abstract: Abstract Despite the increase in therapeutic options, parenteral prostacyclins remain the cornerstone in the medical management of pulmonary arterial hypertension (PAH). While the use of parenteral prostacyclins in pediatric patients is well documented, less is… read more here.
Keywords: transitioning parenteral; hypertension; parenteral prostacyclins; selexipag ... See more keywords
Future Applications of the Selective Prostacyclin (IP) Receptor Agonist Selexipag in Pediatric Pulmonary Hypertension
Sign Up to like & getrecommendations! Published in 2017 at "Pediatric Cardiology"
DOI: 10.1007/s00246-017-1699-1
Abstract: To the Editor, We read with interest the article ‘‘Single-Center Experience Using Selexipag in a Pediatric Population’’ by Gallotti et al. [1]. The authors describe their experience with the selective prostacyclin (IP) receptor agonist selexipag… read more here.
Keywords: cardiac catheterization; hypertension; selexipag; pah ... See more keywords
Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2022 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2022.101592
Abstract: The effective therapy for pulmonary arterial hypertension (PAH) with inadequate clinical response is scarce except for lung transplantation when prostacyclin infusion is ineffective. The purpose of this study is to investigate the efficacy and safety… read more here.
Keywords: infusion; selexipag; infusion analogs; pulmonary arterial ... See more keywords
Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.
Sign Up to like & getrecommendations! Published in 2022 at "Cardiology in the young"
DOI: 10.1017/s1047951122000415
Abstract: OBJECTIVE This study aimed to investigate the safety, tolerability, and efficacy of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension. METHODS This retrospective cohort study included clinical data from five… read more here.
Keywords: arterial hypertension; selexipag; efficacy; young adults ... See more keywords
Cross-species comparison of the metabolism and excretion of selexipag
Sign Up to like & getrecommendations! Published in 2019 at "Xenobiotica"
DOI: 10.1080/00498254.2018.1444814
Abstract: Abstract 1. The metabolism of the prostacyclin receptor agonist selexipag (NS-304; ACT-293987) and its active metabolite MRE-269 (ACT-333679) has been investigated in liver microsomes and hepatocytes of rats, dogs, and monkeys. MRE-269 formation is the… read more here.
Keywords: cross species; metabolism; selexipag; rats dogs ... See more keywords
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1328052
Abstract: ABSTRACT Introduction: Selexipag is the first oral, non-prostanoid, selective prostacyclin receptor (IP receptor) agonist, approved for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients. Areas covered: This article reviews the clinical pharmacology,… read more here.
Keywords: selexipag; pharmacology; treatment; efficacy safety ... See more keywords
4973Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
Sign Up to like & getrecommendations! Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz746.0032
Abstract: Many PAH patients today have a number of CV comorbidities, yet data on the efficacy and safety of therapies in such patients remain scarce. Most recent PAH clinical trials also include patients with comorbidities. To… read more here.
Keywords: safety; patients comorbidities; pah patients; selexipag ... See more keywords
Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.14365
Abstract: Selexipag is a prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension. Cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT‐333679. This study evaluated the interaction… read more here.
Keywords: selexipag; active metabolite; cyp2c8 inhibitor; clopidogrel cyp2c8 ... See more keywords
S122 Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension
Sign Up to like & getrecommendations! Published in 2018 at "Thorax"
DOI: 10.1136/thorax-2018-212555.128
Abstract: Introduction Pulmonary arterial hypertension (PAH) is a progressive disease with a poor prognosis. In the event-driven GRIPHON study, selexipag significantly reduced the risk of a composite primary endpoint event of morbidity/mortality compared with placebo. Purpose… read more here.
Keywords: arterial hypertension; safety; griphon study; pulmonary arterial ... See more keywords
First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2017 at "Pulmonary Circulation"
DOI: 10.1177/2045893217703369
Abstract: Pulmonary arterial hypertension (PAH) is a complex disease with a poor prognosis. Selexipag is a selective prostacyclin receptor agonist with vasodilatory, anti-proliferative, anti-inflammatory, and pro-angiogenic properties. However, no clinical data on its therapeutic use in… read more here.
Keywords: pulmonary arterial; use oral; selexipag; receptor ... See more keywords
Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
Sign Up to like & getrecommendations! Published in 2019 at "Pulmonary Circulation"
DOI: 10.1177/2045894019862167
Abstract: Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH). However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, side effects, or sociocultural… read more here.
Keywords: prostacyclin; parental prostacyclin; transition; pulmonary arterial ... See more keywords